{"entity":{"id":"nct06737081","kind":"trial","name":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","aka":[],"tldr":"A phase 2 trial of SAL-0951 tablets 4mg in advanced solid tumours, run by Shenzhen Salubris Pharmaceuticals Co., Ltd., now recruiting.","summary":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies is a phase 2 interventional study registered as NCT06737081 by Shenzhen Salubris Pharmaceuticals Co., Ltd., with 60 participants planned, started 2024-09-14 and due to reach its primary completion in 2025-12-31. Interventions recorded: SAL-0951 tablets 4mg and SAL-0951 tablets 5mg.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06737081","url":"https://clinicaltrials.gov/study/NCT06737081"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06737081","phase":"2","setting":"A Parallel, Open-label Phase II Clinical Study of Enarodustat (SAL-0951) Tablets in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","enrolled":60,"outcomes":[]},"route":"/trials/nct06737081/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}